Does myo‐inositol supplementation influence oxidative stress biomarkers in patients with non‐alcoholic fatty liver disease?

Abstract

Abstract Myo‐inositol (MI) is a carbocyclic sugar polyalcohol. MI has known to exert anti‐inflammatory, anti‐oxidant, and anti‐diabetic activities. This study aimed to investigate the effects of MI supplementation on oxidative stress biomarkers in obese patients with non‐alcoholic fatty liver disease (NAFLD). In this double‐blinded placebo‐controlled randomized clinical trial, 51 newly diagnosed obese patients with NAFLD were randomly assigned to receive either MI (4 g/day) or placebo supplements accompanied by dietary recommendations for 8 weeks. Oxidative stress biomarkers, nutritional status, as well as liver enzymes and obesity indices were assessed pre‐ and post‐intervention. A total of 48 patients completed the trial. Although anthropometric measures and obesity indices decreased significantly in both groups, the between‐group differences adjusted for confounders were non‐significant for these parameters, except for weight (p = .049); greater decrease was observed in the MI group. Iron and zinc intakes decreased significantly in both groups; however, between‐group differences were non‐significant at the end of the study. No significant between‐group differences were revealed for other antioxidant micronutrients at the study endpoint. Sense of hunger, feeling to eat, desire to eat sweet and fatty foods reduced significantly in both groups (p < .05), while the feeling of satiety increased significantly in the placebo group (p = .002). No significant between‐group differences were observed for these parameters, except for desire to eat fatty foods; a greater decrease was observed in the MI group (p = .034). Serum levels of glutathione peroxidase (GPx) and superoxide dismutase (SOD) significantly increased in both study groups (p < .05); however, the between‐group differences were non‐significant at the end of the study. Furthermore, the between‐group differences were non‐significant for other oxidative stress biomarkers, except for serum nitric oxide (NO) level; a greater decrease was observed in the MI group. MI supplementation could significantly improve weight, desire to eat fatty foods, serum levels of NO, as well as the aspartate aminotransferase (AST)/ALT ratio.

Keywords

• myo‐inositol (MI)
• non‐alcoholic fatty liver disease (NAFLD)
• obesity
• oxidative stress